![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SELE |
Gene summary for SELE |
![]() |
Gene information | Species | Human | Gene symbol | SELE | Gene ID | 6401 |
Gene name | selectin E | |
Gene Alias | CD62E | |
Cytomap | 1q24.2 | |
Gene Type | protein-coding | GO ID | GO:0002090 | UniProtAcc | P16581 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6401 | SELE | P2T-E | Human | Esophagus | ESCC | 2.96e-09 | 9.01e-01 | 0.1177 |
6401 | SELE | P38T-E | Human | Esophagus | ESCC | 3.60e-04 | 2.01e-01 | 0.127 |
6401 | SELE | P61T-E | Human | Esophagus | ESCC | 1.63e-06 | 6.22e-02 | 0.099 |
6401 | SELE | P80T-E | Human | Esophagus | ESCC | 2.02e-02 | 5.43e-02 | 0.155 |
6401 | SELE | P127T-E | Human | Esophagus | ESCC | 7.96e-04 | 2.63e-02 | 0.0826 |
6401 | SELE | P128T-E | Human | Esophagus | ESCC | 5.36e-31 | 1.16e+00 | 0.1241 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19035551 | Stomach | CAG with IM | regulation of tumor necrosis factor superfamily cytokine production | 21/1050 | 186/18723 | 1.79e-03 | 1.92e-02 | 21 |
GO:001583311 | Stomach | CAG with IM | peptide transport | 27/1050 | 264/18723 | 1.92e-03 | 2.02e-02 | 27 |
GO:007005911 | Stomach | CAG with IM | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 10/1050 | 63/18723 | 2.50e-03 | 2.46e-02 | 10 |
GO:00309681 | Stomach | CAG with IM | endoplasmic reticulum unfolded protein response | 11/1050 | 74/18723 | 2.66e-03 | 2.58e-02 | 11 |
GO:000599611 | Stomach | CAG with IM | monosaccharide metabolic process | 26/1050 | 257/18723 | 2.67e-03 | 2.58e-02 | 26 |
GO:00716771 | Stomach | CAG with IM | positive regulation of mononuclear cell migration | 10/1050 | 65/18723 | 3.17e-03 | 2.95e-02 | 10 |
GO:003007311 | Stomach | CAG with IM | insulin secretion | 21/1050 | 195/18723 | 3.17e-03 | 2.95e-02 | 21 |
GO:00712191 | Stomach | CAG with IM | cellular response to molecule of bacterial origin | 23/1050 | 221/18723 | 3.21e-03 | 2.96e-02 | 23 |
GO:00466511 | Stomach | CAG with IM | lymphocyte proliferation | 28/1050 | 288/18723 | 3.33e-03 | 3.03e-02 | 28 |
GO:00708731 | Stomach | CAG with IM | regulation of glycogen metabolic process | 7/1050 | 36/18723 | 3.41e-03 | 3.08e-02 | 7 |
GO:001931811 | Stomach | CAG with IM | hexose metabolic process | 24/1050 | 237/18723 | 3.77e-03 | 3.31e-02 | 24 |
GO:0032943 | Stomach | CAG with IM | mononuclear cell proliferation | 28/1050 | 291/18723 | 3.84e-03 | 3.37e-02 | 28 |
GO:00506701 | Stomach | CAG with IM | regulation of lymphocyte proliferation | 23/1050 | 225/18723 | 4.01e-03 | 3.47e-02 | 23 |
GO:0032944 | Stomach | CAG with IM | regulation of mononuclear cell proliferation | 23/1050 | 227/18723 | 4.47e-03 | 3.76e-02 | 23 |
GO:00706651 | Stomach | CAG with IM | positive regulation of leukocyte proliferation | 17/1050 | 150/18723 | 4.49e-03 | 3.77e-02 | 17 |
GO:00327601 | Stomach | CAG with IM | positive regulation of tumor necrosis factor production | 13/1050 | 103/18723 | 4.96e-03 | 4.01e-02 | 13 |
GO:00716752 | Stomach | CAG with IM | regulation of mononuclear cell migration | 14/1050 | 115/18723 | 5.03e-03 | 4.05e-02 | 14 |
GO:00431616 | Stomach | CAG with IM | proteasome-mediated ubiquitin-dependent protein catabolic process | 36/1050 | 412/18723 | 5.70e-03 | 4.45e-02 | 36 |
GO:00712161 | Stomach | CAG with IM | cellular response to biotic stimulus | 24/1050 | 246/18723 | 5.99e-03 | 4.63e-02 | 24 |
GO:000609121 | Stomach | CSG | generation of precursor metabolites and energy | 83/1034 | 490/18723 | 2.95e-20 | 3.12e-17 | 83 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05418211 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa05417211 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa0493310 | Esophagus | ESCC | AGE-RAGE signaling pathway in diabetic complications | 72/4205 | 100/8465 | 4.15e-06 | 2.28e-05 | 1.17e-05 | 72 |
hsa05418310 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
hsa0466817 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa05417310 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa0493317 | Esophagus | ESCC | AGE-RAGE signaling pathway in diabetic complications | 72/4205 | 100/8465 | 4.15e-06 | 2.28e-05 | 1.17e-05 | 72 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
SELE | CD44 | SELE_CD44 | SELE | Breast | ADJ |
SELE | GLG1 | SELE_GLG1 | SELE | Breast | ADJ |
SELPLG | SELE | SELPLG_SELE | SELPLG | Breast | ADJ |
SELE | CD44 | SELE_CD44 | SELE | Breast | Healthy |
SELE | GLG1 | SELE_GLG1 | SELE | Breast | Healthy |
SELPLG | SELE | SELPLG_SELE | SELPLG | Breast | Healthy |
SELE | CEACAM1 | SELE_CEACAM1 | CEACAM | Breast | Healthy |
SELE | CD44 | SELE_CD44 | SELE | Breast | Precancer |
SELE | CD44 | SELE_CD44 | SELE | Cervix | ADJ |
SELE | GLG1 | SELE_GLG1 | SELE | Cervix | ADJ |
SELPLG | SELE | SELPLG_SELE | SELPLG | Cervix | ADJ |
SELE | CD44 | SELE_CD44 | SELE | Cervix | CC |
SELE | GLG1 | SELE_GLG1 | SELE | Cervix | CC |
SELE | CEACAM1 | SELE_CEACAM1 | CEACAM | Cervix | CC |
SELPLG | SELE | SELPLG_SELE | SELPLG | Cervix | CC |
SELE | CD44 | SELE_CD44 | SELE | Endometrium | ADJ |
SELE | GLG1 | SELE_GLG1 | SELE | Endometrium | ADJ |
SELPLG | SELE | SELPLG_SELE | SELPLG | Endometrium | ADJ |
SELE | CD44 | SELE_CD44 | SELE | Endometrium | AEH |
SELE | GLG1 | SELE_GLG1 | SELE | Endometrium | AEH |
Page: 1 2 3 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SELE | SNV | Missense_Mutation | c.80N>G | p.Ser27Cys | p.S27C | P16581 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
SELE | SNV | Missense_Mutation | novel | c.464N>G | p.Val155Gly | p.V155G | P16581 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SELE | insertion | In_Frame_Ins | novel | c.465_466insACT | p.Val155_Glu156insThr | p.V155_E156insT | P16581 | protein_coding | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
SELE | SNV | Missense_Mutation | c.1681N>T | p.Leu561Phe | p.L561F | P16581 | protein_coding | deleterious(0.01) | probably_damaging(0.913) | TCGA-Q1-A5R3-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR | |
SELE | SNV | Missense_Mutation | c.113N>A | p.Ala38Asp | p.A38D | P16581 | protein_coding | tolerated(0.57) | benign(0.009) | TCGA-VS-A9UB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SELE | SNV | Missense_Mutation | novel | c.518A>G | p.Lys173Arg | p.K173R | P16581 | protein_coding | tolerated(0.53) | benign(0.003) | TCGA-ZJ-AB0H-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
SELE | SNV | Missense_Mutation | c.1408N>G | p.Ser470Ala | p.S470A | P16581 | protein_coding | tolerated(0.13) | benign(0.217) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
SELE | SNV | Missense_Mutation | c.113N>T | p.Ala38Val | p.A38V | P16581 | protein_coding | tolerated(0.25) | benign(0.069) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SELE | SNV | Missense_Mutation | novel | c.544G>A | p.Ala182Thr | p.A182T | P16581 | protein_coding | tolerated(0.24) | possibly_damaging(0.543) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SELE | SNV | Missense_Mutation | c.1758G>T | p.Lys586Asn | p.K586N | P16581 | protein_coding | deleterious(0) | benign(0.42) | TCGA-AZ-4614-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | leucovorin | LEUCOVORIN | 24980946 | |
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | BIMOSIAMOSE | BIMOSIAMOSE | ||
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | fluorouracil | FLUOROURACIL | 24980946 | |
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | capecitabine | CAPECITABINE | 24980946 | |
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL1215923 | BIMOSIAMOSE | |
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | Bimosiamose | BIMOSIAMOSE | ||
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | GMI-1359 | |||
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | GMI-1070 | RIVIPANSEL | 20508165 | |
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | antagonist | CHEMBL3707446 | RIVIPANSEL | |
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | SIALYL LEWIS X | SIALYL LEWIS X |
Page: 1 2 |